Manufacturer of Controlled Substances; Notice of Application; Lin Zhi International Inc., 30326-30327 [2012-12326]

Download as PDF 30326 Federal Register / Vol. 77, No. 99 / Tuesday, May 22, 2012 / Notices Summary of Information Collection DEPARTMENT OF JUSTICE (1) Type of Information Collection: Extension of a currently approved collection. (2) Title of the Form/Collection: Notification of Change of Mailing or Premise Address. (3) Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection: Form Number: None. Bureau of Alcohol, Tobacco, Firearms and Explosives. (4) Affected public who will be asked or required to respond, as well as a brief abstract: Primary: Not-for-profitinstitutions. Other: Business or other for-profit. Drug Enforcement Administration Need for Collection Amphetamine (1100) .................... Methadone (9250) ........................ Morphine (9300) ........................... Licensees and permittees whose mailing address will change must notify the Chief, Federal Explosives Licensing Center, at least 10 days before the change. The information is used by ATF to identify correct locations of storage of explosives licensees/permittees and location of storage of explosive materials for purposes of inspection, as well as to notify permittee/licensees of any change in regulations or laws that may affect their business activities. (5) An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: It is estimated that 1,000 respondents will take 10 minutes to respond via letter to the Federal Explosives Licensing Center. (6) An estimate of the total public burden (in hours) associated with the collection: There are an estimated 170 annual total burden hours associated with this collection. If additional information is required contact: Jerri Murray, Department Clearance Officer, Policy and Planning Staff, Justice Management Division, Department of Justice, Two Constitution Square, Room 2E–508, 145 N Street NE., Washington, DC 20530. Jerri Murray, Department Clearance Officer, PRA, U.S. Department of Justice. [FR Doc. 2012–12346 Filed 5–21–12; 8:45 am] srobinson on DSK4SPTVN1PROD with NOTICES BILLING CODE 4410–FY–P VerDate Mar<15>2010 18:46 May 21, 2012 Jkt 226001 Importer of Controlled Substances; Notice Of Registration; Mylan Pharmaceuticals, Inc. Dated: May 15, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2012–12382 Filed 5–21–12; 8:45 am] BILLING CODE 4410–09–P By Notice dated February 23, 2012, and published in the Federal Register on March 1, 2012, 77 FR 12620, Mylan Pharmaceuticals, Inc., 781 Chestnut Ridge Road, Morgantown, West Virginia 26505, made application by letter to the Drug Enforcement Administration (DEA) to be registered as an importer of the following basic classes of controlled substances: Drug Schedule II II II The company plans to import the listed controlled substances in finished dosage form (FDF) from foreign sources for analytical testing and clinical trials in which the foreign FDF will be compared to the company’s own domestically-manufactured FDF. This analysis is required to allow the company to export domesticallymanufactured FDF to foreign markets. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Mylan Pharmaceuticals, Inc. to import the basic classes of controlled substances is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Mylan Pharmaceuticals, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application; Lin Zhi International Inc. Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 19, 2012, Lin Zhi International Inc., 670 Almanor Avenue, Sunnyvale, California 94085, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Tetrahydrocannabinols (7370) ..... 3,4– Methylenedioxymethamphetamine (7405). Cocaine (9041) ............................. Oxycodone (9143) ........................ Hydrocodone (9193) ..................... Methadone (9250) ........................ Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... Schedule I I II II II II II II The company plans to manufacture the listed controlled substances as bulk reagents for use in drug abuse testing. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than July 23, 2012. E:\FR\FM\22MYN1.SGM 22MYN1 30327 Federal Register / Vol. 77, No. 99 / Tuesday, May 22, 2012 / Notices Dated: May 15, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances, Notice of Application, Alltech Associates, Inc. [FR Doc. 2012–12326 Filed 5–21–12; 8:45 am] BILLING CODE 4410–09–P Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 19, 2012, Alltech Associates Inc., 2051 Waukegan Road, Deerfield, Illinois 60015, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice Of Application; Research Triangle Institute Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 12, 2012, Research Triangle Institute, Hermann Building, East Institute Drive, P.O. Box 12194, Research Triangle, North Carolina 27709, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Schedule Marihuana (7360) ......................... Cocaine (9041) ............................. I II srobinson on DSK4SPTVN1PROD with NOTICES The Institute will manufacture marihuana, and cocaine derivatives for use by their customers in analytical kits, reagents, and reference standards as directed by the National Institute on Drug Abuse. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than July 23, 2012. Dated: May 15, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2012–12381 Filed 5–21–12; 8:45 am] BILLING CODE 4410–09–P VerDate Mar<15>2010 17:20 May 21, 2012 Jkt 226001 Drug Drug Schedule Methcathinone (1237) .................. N-Ethylamphetamine (1475) ........ N,N-Dimethylamphetamine (1480) 4-Methylaminorex (cis isomer) (1590). Alpha-ethyltryptamine (7249) ....... Lysergic acid diethylamide (7315) 2,5-Dimethoxy-4-(n)propylthiophenethylamine (7348). Tetrahydrocannabinols (7370) ..... Mescaline (7381) .......................... 4-Bromo-2,5-dimethoxy-amphetamine (7391). 4-Bromo-2,5dimethoxyphenethylamine (7392). 4-Methyl-2,5-dimethoxy-amphetamine (7395). 2,5-Dimethoxyamphetamine (7396). 2,5-Dimethoxy-4ethylamphetamine (7399). 3,4-Methylenedioxyamphetamine (7400). N-Hydroxy-3,4methylenedioxyamphetamine (7402). 3,4-Methylenedioxy-Nethylamphetamine (7404). 3,4Methylenedioxymethamphetamine (7405). 4-Methoxyamphetamine (7411) ... Alpha-methyltryptamine (7432) .... Bufotenine (7433) ......................... Diethyltryptamine (7434) .............. Dimethyltryptamine (7435) ........... Psilocybin (7437) .......................... Psilocyn (7438) ............................. 5-Methoxy-N,Ndiisopropyltryptamine (7439). N-Ethyl-1-phenylcyclohexylamine (7455). 1-(1-Phenylcyclohexyl)pyrrolidine (7458). 1-[1-(2-Thienyl)cyclohexyl]piperidine (7470). Dihydromorphine (9145) ............... Heroin (9200) ............................... Normorphine (9313) ..................... Methamphetamine (1105) ............ 1-phenylcyclohexylamine (7460) II Phencyclidine (7471). PO 00000 Frm 00068 Fmt 4703 Sfmt 4703 I I I I I I I I I I I I Phenylacetone (8501) .................. 1piperidinocyclohexanecarbonitrile (8603). Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) VII. Ecgonine (9180) ........................... Meperidine intermediate-B (9233) Noroxymorphone (9668) VII. Schedule II II II II II II The company plans to manufacture high purity drug standards used for analytical applications only in clinical, toxicological, and forensic laboratories. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than July 23, 2012. Dated: May 15, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2012–12379 Filed 5–21–12; 8:45 am] BILLING CODE 4410–09–P I I DEPARTMENT OF LABOR I Approval of Information Collection Requirements; Comment Request I Office of Federal Contract Compliance Programs, Labor. ACTION: Notice. AGENCY: I I I I I I I I I I I I I I I I II II The Department of Labor, as part of its continuing effort to reduce paperwork and respondent burden, conducts a pre-clearance consultation program to provide the general public and Federal agencies with an opportunity to comment on proposed and continuing collections of information in accordance with the Paperwork Reduction Act of 1995 (PRA). 44 U.S.C. 3506(c)(2)(A). This program helps to ensure that requested data can be provided in the desired format, reporting burden (time and financial resources) is minimized, collection instruments are clearly understood, and the impact of collection requirements on respondents can be properly assessed. Currently, the Office of Federal Contract Compliance Programs is soliciting comments on its SUMMARY: E:\FR\FM\22MYN1.SGM 22MYN1

Agencies

[Federal Register Volume 77, Number 99 (Tuesday, May 22, 2012)]
[Notices]
[Pages 30326-30327]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-12326]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application; Lin 
Zhi International Inc.

    Pursuant to Sec.  1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on April 19, 2012, Lin Zhi 
International Inc., 670 Almanor Avenue, Sunnyvale, California 94085, 
made application by renewal to the Drug Enforcement Administration 
(DEA) to be registered as a bulk manufacturer of the following basic 
classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)...............  I
3,4-Methylenedioxymethamphetamine (7405)...  I
Cocaine (9041).............................  II
Oxycodone (9143)...........................  II
Hydrocodone (9193).........................  II
Methadone (9250)...........................  II
Dextropropoxyphene, bulk (non-dosage forms)  II
 (9273).
Morphine (9300)............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
as bulk reagents for use in drug abuse testing.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than July 23, 2012.


[[Page 30327]]


    Dated: May 15, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2012-12326 Filed 5-21-12; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.